Symbio Generrics

Symbio Generrics India Private Limited, established in 2011, operates as a specialized manufacturer and marketer of Active Pharmaceutical Ingredients (APIs) and intermediates. Founded by pharmaceutical industry professionals Salim Shaikh, Abhijit Govindrao Kale, Akash Suresh Puranik, and Lakshmi Reddy Devalla, the company has transitioned from a sales and marketing entity to a vertically integrated manufacturer. The founders leverage decades of collective experience in the global pharmaceutical sector to guide the company's strategy. A significant milestone was achieved in November 2022, when Symbio secured a substantial equity investment from Ascent Capital, a growth-capital focused private equity fund. This funding is earmarked for strategic acquisitions, enhancing manufacturing capacity, and establishing a high-standard R&D facility.

The company's business model is centered on the development, manufacturing, and global supply of generic APIs, catering to a diverse clientele that includes pharmaceutical, life sciences, biotechnology, agrochemical, and specialty chemical companies. Symbio Generrics also engages in contract development and manufacturing organization (CDMO) services, partnering with firms for the creation of advanced intermediates and APIs for both regulated and emerging markets. Revenue is generated through the sale of these products and services via a well-established global distribution network. For the fiscal year ending March 31, 2024, the company reported a revenue of ₹489Cr.

Symbio's operational infrastructure includes a state-of-the-art R&D center in Jigani, Bengaluru, and two fully integrated API manufacturing facilities. One plant is located in Achutapuram, Visakhapatnam, and the other, VPL Chemicals Pvt Ltd, is a fully owned subsidiary located near Bengaluru. The company is committed to adhering to international regulatory, production, and quality control standards, offering Drug Master Files (DMFs) for its specialty APIs and securing registrations in various global markets. This focus on quality and regulatory compliance allows them to serve leading generic companies worldwide.

Keywords: Active Pharmaceutical Ingredients, API manufacturing, pharmaceutical intermediates, generic APIs, contract development manufacturing organization, CDMO, life sciences, specialty chemicals, pharmaceutical marketing, global API supply, drug master files, Ascent Capital, Salim Shaikh, Akash Puranik, Abhijit Kale, pharmaceutical R&D, VPL Chemicals, Vizag manufacturing, Bengaluru manufacturing, generic drug development